Genzyme 1Q11

1Q Revenues: $1.0 billion (+7%)

Comments: Personalized Genetic Health business grew 11% to $436.9 million. Myozyme / Lumizyme sales grew 47% in the quarter to $126.8 million. Cerezyme sales were $183.8 million (+3%). Sales of Fabrazyme were down 23% to $40.9 million, reflecting supply constraints. The company’s Hematology and Oncology business grew 7% to $166.5 million, driven by U.S. growth of Clolar, continued market penetration of Mozobil, and growth of Thymoglobulin. Sales of Renvela and Renagel grew 14% to $187.4 million. Sales of Thyrogen were down due to supply shortages caused by manufacturing constraints. Genzyme was acquired by Sanofi-Aventis on April 8, 2011.